Medimmune stops arthritis and psoriasis trials

By Staff Writers
Tuesday, 31 August, 2004

Maryland-based MedImmune has halted the clinical trials of its Vitaxin drug for rheumatoid arthritis and psoriasis, blaming a lack of benefits seen with the experimental treatment.

The drug maker said no safety issues came up during the trial. It will continue to study the compound to treat cancer.

Babies of stressed mothers likely to get their teeth earlier

Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...

Customised immune cells used to fight brain cancer

Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...

Elevated blood protein levels predict mortality

Proteins that play key roles in the development of diseases such as cancer and inflammation may...

Content from other channels on our network

Eggless muffins using clean-label texturiser

Six beverage trends predicted for 2026

Mars receives final approval for its Kellanova acquisition

Making UHT processing less intensive on energy

Tasty twist for chocolate alternatives

AR3 to be first to process rare earths at ANSTO's new pilot facility

Defence Trailblazer funding manufacturing to help Defence and industry transition to clean energy

Fitzroy River Water chooses Honeywell SCADA

Titomic announces breakthrough in lithium‍-‍ion electrode manufacturing

Advantech signs Centralian Controls as channel partner

Helping to keep health care professionals hands-on

Fundamental reimagining: new Sydney Children's Hospital, Randwick

A Day in the Life of a health equity consultant and street health nurse

$1bn vaccine and antivenom manufacturing facility opens

In Conversation with Australasian Institute of Digital Health CEO Anja Nikolic